Stem cell shot during bypass aims to rebuild failing hearts

NCT ID NCT07496372

Recruiting now Disease control Sponsor: HELP Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether injecting lab-grown heart muscle cells (HiCM-188) into the heart during bypass surgery can help people with severe heart failure (NYHA class III-IV). Eighty participants will receive either the stem cells plus bypass or bypass alone. The main goal is to see if they can walk farther in 6 minutes, with other measures including survival and heart function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: human induced pluripotent stem cell-derived cardiomyocytes (HiCM-188)
What this could lead to: If it works, this could offer a new way to repair damaged heart muscle in people with severe heart failure, potentially improving their ability to walk and reducing hospitalizations.
What could go wrong: This is an early Phase 3 trial with only 80 participants, so results may not apply to everyone. Stem cell therapies carry risks like immune reactions or arrhythmias, and the long-term effects are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

advanced heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

TEDA International Cardiovascular Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300457, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.